Cytokinetics will sell percentage of royalties on heart failure drug for $90 million By: MarketWatch February 02, 2017 at 07:30 AM EST The late-stage drug is being developed by Amgen and Cytokinetics. Read More >> Related Stocks: Amgen Cytokinetics Standard & Poors 500